. . . . . . . . . . . . . "p(HGNC:IL13) -| p(HGNC:CXCL5)" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "Further, IL-13 was most potent at reducing RA ST explant ENA-78 levels compared with other inflammatory mediators that we examined (Fig. 3 B )." . . "Selventa" . . . . "2014-07-03T14:29:52.030+02:00"^^ . . .